Compass Therapeutics, Inc. CMPX
Compass Therapeutics, Inc. (Nasdaq: CMPX) is an oncology drug developer. Its lead program, Tovecimig (CTX-009), is in Phase 3 for Biliary tract cancer (second-line). Its next catalyst on record is CTX-8371 / CTX-10726: Clinical data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CTX-8371 / CTX-10726 — Clinical data (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Tovecimig (CTX-009) | Biliary tract cancer (COMPANION-002 Phase 2/3) | antibody | Phase 3 |
| CTX-471 | Solid tumors | antibody | Phase 1 |
| CTX-8371 | Solid tumors | antibody | Phase 1 |
| CTX-10726 | Solid tumors | antibody | Phase 1 |
Recent results and decisions
- Apr 27, 2026met Primary ORR endpoint previously met (17.1% vs 5.3%, p=0.031); new secondaries: PFS 4.7 vs 2.6 months (HR 0.44, p<0.0001) but OS not met (HR 1.05, p=0.78) due to 54% crossover.
Tovecimig did not meet the OS secondary endpoint due to high crossover from the control arm (31 of 57 patients, or 54%) and prolonged survival of those crossover patients after receiving tovecimig
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.